Developing vaccines and antibodies for rubulaviruses
Prototype strategy for vaccines and antibodies to rubulaviruses
This study is working on developing better vaccines to protect against rubulaviruses, which can spread easily and cause respiratory illnesses, by looking closely at how the virus works and how our immune system responds, so we can create stronger defenses for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10863698 on NIH RePORTER |
What this research studies
This research focuses on creating effective vaccines and antibodies to combat rubulaviruses, which are highly transmissible respiratory pathogens. The team will study the structure and function of specific viral proteins to design stabilized vaccine candidates. They will use advanced techniques, including cryoelectron tomography, to understand how these proteins interact with the virus and the immune system. By isolating and characterizing immune cells from vaccinated individuals, they aim to enhance the design of these vaccines and assess their effectiveness in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk of infection from rubulaviruses or those who may benefit from enhanced vaccine strategies.
Not a fit: Patients who are not at risk for rubulavirus infections or who have already been vaccinated against these viruses may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines and treatments for diseases caused by rubulaviruses, potentially improving public health outcomes.
How similar studies have performed: Previous research has shown promise in developing vaccines for similar viral pathogens, indicating that this approach could yield successful outcomes.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Duprex, William Paul — Washington University
- Study coordinator: Duprex, William Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.